Immuneering [IMRX] vs Invivyd [IVVD] Detailed Stock Comparison
Immuneering
NASDAQ
Loading...
Invivyd
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Immuneering wins in 8 metrics, Invivyd wins in 7 metrics, with 0 ties. Immuneering appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Immuneering | Invivyd | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.70 | -0.80 | Immuneering |
| Price-to-Book Ratio | 6.85 | 3.20 | Invivyd |
| Debt-to-Equity Ratio | 13.83 | 6.93 | Invivyd |
| PEG Ratio | 0.18 | 0.01 | Invivyd |
| EV/EBITDA | -2.79 | -0.94 | Immuneering |
| Profit Margin (TTM) | 0.00% | -238.33% | Immuneering |
| Operating Margin (TTM) | 0.00% | -127.78% | Immuneering |
| Return on Equity | -130.47% | -120.08% | Invivyd |
| Return on Assets (TTM) | -68.37% | -53.25% | Invivyd |
| Free Cash Flow (TTM) | $-55.08M | $-170.63M | Immuneering |
| 1-Year Return | 366.95% | 40.74% | Immuneering |
| Price-to-Sales Ratio (TTM) | N/A | 5.17 | N/A |
| Enterprise Value | $177.76M | $105.02M | Immuneering |
| EV/Revenue Ratio | N/A | 2.27 | N/A |
| Gross Profit Margin (TTM) | N/A | 94.19% | N/A |
| Revenue per Share (TTM) | $0 | $0 | Invivyd |
| Earnings per Share (Diluted) | $-1.90 | $-0.92 | Invivyd |
| Beta (Stock Volatility) | 0.43 | 0.55 | Immuneering |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Immuneering vs Invivyd Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Immuneering | 0.92% | -4.17% | 54.34% | 168.78% | 267.33% | 149.32% |
| Invivyd | 14.23% | 17.53% | 58.33% | 22.58% | 7.55% | 137.50% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Immuneering | 366.95% | -37.88% | -68.68% | -68.68% | -68.68% | -68.68% |
| Invivyd | 40.74% | -75.22% | -94.54% | -94.54% | -94.54% | -94.54% |
Performance & Financial Health Analysis: Immuneering vs Invivyd
| Metric | IMRX | IVVD |
|---|---|---|
| Market Information | ||
| Market Cap | $234.99M | $238.69M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 916,790 | 26,090,460 |
| 90 Day Avg. Volume | 737,707 | 9,430,330 |
| Last Close | $5.51 | $1.14 |
| 52 Week Range | $1.10 - $6.35 | $0.35 - $2.74 |
| % from 52W High | -13.23% | -58.39% |
| All-Time High | $33.99 (Aug 02, 2021) | $78.82 (Nov 29, 2021) |
| % from All-Time High | -83.79% | -98.55% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 4.21% |
| Quarterly Earnings Growth | N/A | 4.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -2.38% |
| Operating Margin (TTM) | 0.00% | -1.28% |
| Return on Equity (TTM) | -1.30% | -1.20% |
| Debt to Equity (MRQ) | 13.83 | 6.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.80 | $0.36 |
| Cash per Share (MRQ) | $0.73 | $0.29 |
| Operating Cash Flow (TTM) | $-51,509,300 | $-113,108,000 |
| Levered Free Cash Flow (TTM) | $-29,878,488 | $-47,749,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Immuneering vs Invivyd
| Metric | IMRX | IVVD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.70 | -0.80 |
| Forward P/E | -3.36 | -5.70 |
| PEG Ratio | 0.18 | 0.01 |
| Price to Sales (TTM) | N/A | 5.17 |
| Price to Book (MRQ) | 6.85 | 3.20 |
| Market Capitalization | ||
| Market Capitalization | $234.99M | $238.69M |
| Enterprise Value | $177.76M | $105.02M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 2.27 |
| Enterprise to EBITDA | -2.79 | -0.94 |
| Risk & Other Metrics | ||
| Beta | 0.43 | 0.55 |
| Book Value per Share (MRQ) | $0.80 | $0.36 |
Financial Statements Comparison: Immuneering vs Invivyd
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IMRX | IVVD |
|---|---|---|
| Revenue/Sales | $0 | $11.79M |
| Cost of Goods Sold | N/A | $685,000 |
| Gross Profit | N/A | $11.10M |
| Research & Development | $11.47M | $9.57M |
| Operating Income (EBIT) | $-15.49M | $-15.06M |
| EBITDA | $-15.39M | $-14.56M |
| Pre-Tax Income | $-15.05M | $-14.66M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-15.05M | $-14.66M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IMRX | IVVD |
|---|---|---|
| Cash & Equivalents | $35.87M | $48.08M |
| Total Current Assets | $38.21M | $75.83M |
| Total Current Liabilities | $5.11M | $49.60M |
| Long-Term Debt | $3.73M | N/A |
| Total Shareholders Equity | $41.84M | $54.15M |
| Retained Earnings | $-239.34M | $-918.28M |
| Property, Plant & Equipment | $4.82M | $2.48M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IMRX | IVVD |
|---|---|---|
| Operating Cash Flow | $-13.66M | $-12.47M |
| Capital Expenditures | $-8,945 | $-144,000 |
| Free Cash Flow | $-14.09M | $-21.27M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IMRX | IVVD |
|---|---|---|
| Shares Short | 1.58M | 3.05M |
| Short Ratio | 3.83 | 4.10 |
| Short % of Float | 0.06% | 0.04% |
| Average Daily Volume (10 Day) | 916,790 | 26,090,460 |
| Average Daily Volume (90 Day) | 737,707 | 9,430,330 |
| Shares Outstanding | 31.05M | 119.84M |
| Float Shares | 28.65M | 72.18M |
| % Held by Insiders | 0.24% | 0.19% |
| % Held by Institutions | 0.11% | 0.49% |
Dividend Analysis & Yield Comparison: Immuneering vs Invivyd
| Metric | IMRX | IVVD |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |